Oxford–AstraZeneca COVID-19 vaccine: need of a reasoned and effective vaccine campaign

A strong COVID-19 vaccine campaign is needed to reach the herd immunity and reduce this pandemic infection. In the Foch Hospital, France, in February 2021, 451 healthcare workers were vaccinated by a first dose of AstraZeneca vaccine. Adverse effects were reported to our pharmaco-vigilance circuit,...

Full description

Saved in:
Bibliographic Details
Published in:Public health (London) 2021-07, Vol.196, p.135-137
Main Authors: Vallée, A., Chan-Hew-Wai, A., Bonan, B., Lesprit, P., Parquin, F., Catherinot, É., Choucair, J., Billard, D., Amiel-Taieb, C., Camps, È., Cerf, C., Zucman, D., Fourn, E.
Format: Article
Language:English
Subjects:
Adverse effects
Arthralgia
AstraZeneca vaccine
Campaigns
Chills
Circuits
Coronaviruses
COVID-19
COVID-19 vaccine
COVID-19 Vaccines
Discomfort
Efficacy
Fatigue
Fever
Health care
Herd immunity
Humans
Immunity
Immunization
Medical personnel
Muscles
Muscular fatigue
Pain
Pandemics
Pandemics - prevention & control
Privacy
SARS-CoV-2
Short Communication
Side effects
Uncertainty
Vaccination
Vaccine campaign
Vaccines
Vigilance
Workers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A strong COVID-19 vaccine campaign is needed to reach the herd immunity and reduce this pandemic infection. In the Foch Hospital, France, in February 2021, 451 healthcare workers were vaccinated by a first dose of AstraZeneca vaccine. Adverse effects were reported to our pharmaco-vigilance circuit, by an online and anonymous questionnaire following the first weeks of the vaccinal campaign to healthcare workers. Two hundred seventy-four (60.8%) of them reported multiple adverse effects. Main adverse effects reported were feverish state/chills (65.7%), fatigue/physical discomfort (62.4%), arthralgia/muscle pain (61.0%) and fever (44.5%). On March 2021 many European countries suspended AstraZeneca vaccine for one week due to safety uncertainty. Thus, confidence in its efficacy is undermined. However, the benefit/risk balance is clearly in favor of vaccination.
ISSN:0033-3506
1476-5616
DOI:10.1016/j.puhe.2021.05.030